Navigation Links
Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
Date:11/13/2007

stech.com" target="_new">http://www.nastech.com to access a live Webcast or the subsequent 30-day archive. Please connect to the Investor section of Nastech's Website several minutes prior to the start of the live conference call to ensure adequate time for any software download that may be necessary.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward-Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
2. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...ire/ -- Susan Knapp Pinnas, a leader of provider,... diversified healthcare,experience, has been name...e,company announced today. , As a member o... be,responsible for advancing AvMed,s overall pro...of strong relationships and service excellence. P...
(Date:1/8/2009)... Lighthouse International and EHE International un...W YORK, Jan. 8 Thousand...e New Year that urges them to take care of their v...nd graciously donated by EHE International, was cr...leader in vision healthcare. It will be on display...
(Date:1/8/2009)...likely to be deadly for women and African-American...enomenon account for only part of the differences ... counterparts, according to results published in t...esults present a stark question for doctors and pa...se upon diagnosis don,t account for all the increa...
(Date:1/8/2009)...sets stage for productive partnership , , BALTI... Recovery Coalition (MARC), a broad-based group to...d the groundwork for improving the Medicare Second...with officials from the Center for Medicare and Me...introduce MARC as an industry resource to CMS and ...
Breaking Medicine News(10 mins):Health News:Susan Knapp Pinnas Named AvMed Health Plans' New Senior Vice President of Network 2Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 2Health News:61 Million Americans are at Risk of Vision Loss and Don't Even Know It 3Health News:Why bladder cancer is deadlier for some 2Health News:Why bladder cancer is deadlier for some 3Health News:Why bladder cancer is deadlier for some 4Health News:MARC Coalition Holds Initial Meeting With CMS; Announces New Members 2
...dra Shekhar today died in the Apollo Hospital of t... cancer of the plasma cell and was admitted in Ma... Shekar, a MA from the Allahabad Universtiy, is su...was born on July 1, 1927. He was a Member of Parl...
...gners Friday criticised three university hospitals...a US tobacco giant for research into smoking. Ph...ch simultaneously in South Korea and Japan, said J...ogy professor at Seoul National University Hospita...
...in Scots are more likely to suffer heart attacks, ...j Bhopal and Colin Fischbacher at the University o...ely to survive this trauma in comparison to their ...As part of the study, the researchers linked infor...
... marble, and a symbol of love continues to enjoy i...World. The tomb of Mumtaj has charmed many throug...ge UNESCO site. The new list of seven wonders fu...n 7.7.07 at Lisbon. The announcement was made at a...
Other Medicine News:
(Date:12/27/2008)...te Boisselier breaks 5-year silence, offers to eas...public , , LAS VEGAS, Dec. 27 /PRNewswire-USNew...Baby Eve, the first cloned child, Dr. Brigitte Boi...d project, said Eve and other babies cloned by her...ith no one invading their families, privacy. , ,...
(Date:12/17/2008)...rgest, Most Complex of Its Kind; 80 Percent of Tra...ND, Dec. 17 A multi-disciplinary t...cently performed the first near-total face transp...r procedure performed within the past two weeks, s...who suffered severe facial trauma -- essentially r...
(Date:12/17/2008)...Dec. 17 Delcath Systems...ntment of Pamela R. Contag, Ph.D., to Delcath,s Bo...e executive with extensive experience working with... (LOGO: http://www.newscom.com/cgi-bin/prnh/200... Cobalt Technologies, Inc. in 2006 and served as C...
(Date:12/16/2008)...tudy finds that colonoscopy is associated with low...n of colorectal cancer on the right side of the co...re-USNewswire/ -- A study released today in the A... is associated with lower death rates from colorec...more often on the right side of the colon versus t...
Breaking Medicine Technology:'We're Ready to Prove It!' 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer 2ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer 3ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer 4ASGE Urges Patients to Seek a Qualified Endoscopist Before Undergoing a Colonoscopy for Colorectal Cancer 5Prozac Reduces Disease Activity in MS Patients 18111 1Prozac Reduces Disease Activity in MS Patients 18111 2Incubators Affect Newborns Heart Rates 18109 1Incubators Affect Newborns Heart Rates 18109 2SXC Health Solutions completes acquisition of NMHC 18107 1SXC Health Solutions completes acquisition of NMHC 18107 2FDA Approves Advair 28R 29 250 50 for Reduction of Exacerbations in Patients With COPD 18105 1FDA Approves Advair 28R 29 250 50 for Reduction of Exacerbations in Patients With COPD 18105 2FDA Approves Advair 28R 29 250 50 for Reduction of Exacerbations in Patients With COPD 18105 3FDA Approves Advair 28R 29 250 50 for Reduction of Exacerbations in Patients With COPD 18105 4
...Functionality in Humans of CTI,s,Programmable, Pul...,ChronoDose, BASEL, Switzerland and TRENTON, N.J.,...Inc. (CTI) announced today the successful,completi...programmable, pulsatile, passive transdermal drug/...tends to publish this,clinical data in leading sci...
...SS WIRE)--May 7, 2007 - NanoViricides,Inc. (Pink ...tudies,against rabies and BSL3 in vitro studies ag...e 23rd Annual Symposium of the Pan,American Societ...,May 2. (Pan American Society for Clinical Virolo... studies against Clade 2 H5N1, a Dec. 2006 isolate...
Other Medicine Technology:Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 2Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device,Combination Product - ChronoDose 3NanoViricides Drugs Found To Be Highly Effective Against Most,Recent Strain of the H5N1 Avian Flu Virus 2
Duckbill. 3.5 mm tip. Light curve.
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle.
2 mm curved tip. Round handle. Designated most popular model or size.
Large. Double-ended. 3 mm pointed end and 5 mm angled end.
Medicine Products: